Amer Sports, Inc. (AS)
Stock analysis · NYSE · Consumer Cyclical · Leisure
Amer Sports, Inc. (AS) is a publicly traded company in the Consumer Cyclical sector. Latest price: $28.19. Market cap $16.40B. Trailing PE 29.06. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →You have viewed 11 SEO analysis pages
Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.
Continue with free signup1-Year Price
Earnings
Proprietary Signals
About Amer Sports, Inc.
Amer Sports, Inc. is a global enterprise dedicated to the creation, production, promotion, and sale of athletic equipment, clothing, footwear, and related accessories. The company's extensive reach covers Europe, the Middle East, Africa, the Americas, China, and the wider Asia Pacific region. Its operations are structured into three main divisions. The Technical Apparel segment focuses on high-performance outdoor wear, shoes, and accessories, primarily under the Arc'teryx and Peak Performance brands. The Outdoor Performance segment supplies a variety of outdoor apparel, footwear, accessories, and winter sports gear from labels such as Salomon, Atomic, Armada, and ENVE. Finally, the Ball & Racquet Sports segment delivers sports equipment, activewear, and accessories, featuring prominent brands like Wilson, DeMarini, Louisville Slugger, EvoShield, and ATEC. Beyond these brand-specific offerings, Amer Sports' product range includes specialized items like climbing gear, hiking and running shoes, skiing and snowboarding equipment, functional athletic apparel, and lifestyle footwear. They also provide sporting goods for popular activities such as tennis, baseball, American football, bas…
Valuation
| P/E (TTM) | 29.06× |
|---|---|
| P/S (TTM) | 2.21× |
| P/B | 2.39× |
| PEG | 0.21× |
| P/FCF (TTM) | 23.91× |
| EV / EBITDA | 12.65× |
| EV / Sales | 2.26× |
| Earnings Yield | 3.33% |
| Free Cash Flow Yield | 4.18% |
Fundamentals
| Enterprise Value | $16.78B |
|---|---|
| Revenue (TTM) | $7.44B |
| Net Income (TTM) | $545.69M |
| Free Cash Flow (TTM) | $689.89M |
| Net Debt | $381.20M |
| Working Capital | $1.50B |
| Gross Margin | 59.81% |
| Operating Margin | 12.41% |
| Net Margin | 7.35% |
| Return on Equity | 8.72% |
| Return on Invested Capital | 7.57% |
Peers
Recent News
- ASO vs. AS: Which Stock Is the Better Value Option?
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Dise…
- Amer Sports Chief Strategy Officer Exercises Options to Acquire More than $7 Million Shares. Is This a Signal to Buy AS?
- New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Di…
- AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026…
Related
Browse more tickers: sitemap